. "Approximately 25%"@en . . "approved"@en . "Eptifibatide inhibits platelet aggregation by reversibly binding to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets, thus preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. Inhibition of platelet aggregation occurs in a dose- and concentration-dependent manner."@en . . "* 55 mL/kg/h [patients with coronary artery disease]"@en . "Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation."@en . "Humans and other mammals"@en . . . . "investigational"@en . . . . "For treatment of myocardial infarction and acute coronary syndrome."@en . "Eptifibatide"@en . . " "@en . "Intrifiban"@en . . . "Approximately 2.5 hours"@en . . "188627-80-7"@en . . . . . "Guojie Ho, Antoinette Paone, Luciano Forni, Catherine De Tollenaere, Brice Bonnet, Christine Devijver, \"Processes for preparing eptifibatide.\" U.S. Patent US20060036071, issued February 16, 2006."@en . "Integrelin"@en . . . . "Eptifibatide was not lethal to rats, rabbits, or monkeys when administered by continuous intravenous infusion for 90 minutes at a total dose of 45 mg/kg (about 2 to 5 times the recommended maximum daily human dose on a body surface area basis)"@en . . . . . . . . . " # Nguyen CM, Harrington RA: Glycoprotein IIb/IIIa receptor antagonists: a comparative review of their use in percutaneous coronary intervention. Am J Cardiovasc Drugs. 2003;3(6):423-36. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/ 14728062"@en . . . .